|
|||||
 |
 |
 |
 |
 |
|
 |
|||||
| Faculty |
||
 |
||
Ian Frank, M.D. Dr. Frank’s main area of research is the use of antiretroviral therapy to treat HIV infection. He has been studying novel approaches to control HIV replication, including the use of antiretroviral treatment interruption and vaccines to augment the HIV specific immune responses as adjuctive HIV therapy. He is also studying the etiologies of the complications of long-term antiretroviral treatment, including hyperlipidemia and insulin resistance. Frank I: Once-daily HAART: toward a new treatment paradigm. Journal of Acquired Immunodeficiency Syndromes. 31S10-15, 2002. Otero M, Nunnari G, Leto D, Sullivan J, Wang F-X, Frank I, Xu Y, Patel C, Dornadula G, Kulkosky J, Pomerantz RJ. Peripheral blood dendritic cells are not a major reservoir for HIV type 1 infected individuals on virally suppressive HAART. AIDS Research and Human Retroviruses, 19:1097-1103, 2003. Tershakovec AM, Frank I, Rader D. HIV-related lipodystrophy and related factors. Atherosclerosis, 174:1-10, 2004. Vogler M, Teppler H, Gelman R, Weng Cherng D, Valentine F, Pomerantz R, Pollard R, Gonzalez C J, Frank I, Lederman M M, Squires K, Mildvan D, Mahon L, Schock B, Bell D, and the AIDS Clinical Trials Group 248 Study Team. Low-dose daily subcutaneous interleukin-2 (IL-2) added to single or dual nucleoside yherapy in HIV infection does not protect against CD4+T cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). Journal of Acquired Immunodeficiency Syndromes. In press. Frank I, Bosch RJ, Fiscus S, Valentine F, Flexner C, Segal Y, Ruan P, Gulick R, Wood K, Estep S, Fox L, Nevin T, Stevens M, and Eron, JJ Jr, for the ACTG 307 Protocol Team. Activity, Safety, and Immunologic Effects of Hydroxyurea Added to Didanosine in Antiretroviral Naïve and Experienced HIV-1 Infected Subjects: A Randomized, Placebo-Controlled Trial, ACTG 307. AIDS Research and Human Retroviruses. In press. Contact:
Education: |
||
